Enodia Therapeutics
PrivateLast Round
Seed
Jan 8, 2026
Total Funding Raised
$25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Enodia Therapeutics is a biotechnology company that develops small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enodia Therapeutics Comparables
Compare Enodia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gate Bioscience | 79% | |
| Initial Therapeutics | 73% | |
| Sibylla Biotech | 71% |
Enodia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 8, 2026 |
Enodia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investsud | Seed |
| Elaia Partners | Seed |
| Wallonie Entreprendre | Seed |
| Pfizer Ventures | Seed |
| Mission BioCapital | Seed |
| Institut Pasteur | Seed |
| Sambrinvest | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 30, 2026
Grew 27% QoQ from 11 to 14 employees.
- Jul 18, 2026
Grew 50% QoQ, from 8 to 12 employees.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Enodia develops novel small-molecule therapies for targeted protein degradation through a platform designed to identify small molecules that enable selective Sec61 translocon modulation.
- is_developingOct 13, 2026
Enodia collaborates with Pfizer to discover and develop Sec61 inhibitors under a deal potentially worth over $500m, with Enodia handling initial discovery and Pfizer taking responsibility for subsequent clinical trials, manufacturing, regulatory submissions, and commercial operations.
- is_developingOct 13, 2026
Enodia plans to develop sec61-targeting small molecules with Pfizer on Oct 13th '26
Enodia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enodia Therapeutics's valuation, stock price, and market status.
Is Enodia Therapeutics a public or private company?
Enodia Therapeutics is a private company.
What is the current stock price of Enodia Therapeutics?
Enodia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Enodia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enodia Therapeutics worth (valuation)?
Valuation information for Enodia Therapeutics is not publicly available.
Can I buy Enodia Therapeutics stock?
Enodia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enodia Therapeutics's last funding round?
Enodia Therapeutics's most recent funding round was Seed on January 8, 2026.
Who are the main investors in Enodia Therapeutics?
Key investors in Enodia Therapeutics include Elaia Partners, Pfizer Ventures, Bpifrance, Pfizer Ventures.
Will Enodia Therapeutics IPO soon?
No public IPO plans have been announced for Enodia Therapeutics.
How can I track Enodia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Enodia Therapeutics's shares on secondary markets.